Nama's AI scorecard currently rates Biogen Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is BIIB's P/E ratio?

Biogen trades at a trailing price-to-earnings ratio of 21.1.

When does BIIB report earnings?

Biogen's next scheduled report is on Feb 5, 2027. Analysts expect EPS of $2.84.

What is the BIIB price target?

The median analyst price target from 32 analysts is $270.00, with a range of $175.00 – $325.00.

Is BIIB Shariah compliant?

Nama's AAOIFI-style screen reads Biogen as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Biogen (BIIB)

Healthcare · Drug Manufacturers General · NASDAQ

S&P 500

Biogen (BIIB) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $36.71B, a trailing price-to-earnings ratio of 21.1 and a free-cash-flow yield of 5.4%. Over the most recent reported fiscal year, revenue grew 2.2% and free cash flow per share fell 22.4%. Nama's AI scorecard rates it Buy, 6.3 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 6.3/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Leading · +41.7% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-22.3%

How far the last close sits under the highest price of the past five years.

Market cap	$36.71B
Trailing P/E	21.1
Price / book	1.9
Price / sales	3.6
FCF yield	5.4%
Dividend yield	—
Gross margin	74.0%
Operating margin	19.3%
Net margin	8.3%
Revenue growth (YoY)	+2.2%
Revenue growth (3-yr annual)	-0.9%
EPS growth (YoY)	-7.2%
FCF/share growth (YoY)	-22.4%
Beta	0.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers General

BIIB earnings

Next report: Feb 5, 2027 (Q4 2026, EPS estimate $2.84). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 28, 2026	$2.62	$1.99	+31.7%	$2.80B
Q2 2026	Jul 29, 2026	$3.60	$2.03	+77.3%	$2.74B
Q1 2026	Apr 29, 2026	$3.57	$2.95	+21.0%	$2.48B
Q4 2025	Feb 6, 2026	$1.99	$1.62	+22.8%	$2.28B

BIIB analyst price target

Median target $270.00 from 32 analysts, ranging $175.00 – $325.00.

Drug Manufacturers General peers

Ticker	Company	Market cap	P/E
LLY	Eli Lilly	$1.21T	42.4
JNJ	Johnson & Johnson	$664.95B	25.9
ABBV	AbbVie	$514.92B	22.7
MRK	Merck	$361.73B	47.0
NVS	Novartis	$307.00B	19.0
AZN	AstraZeneca	$289.14B	38.8
AMGN	Amgen	$249.05B	19.9
GILD	Gilead Sciences	$207.00B	—

Explore live BIIB data on Nama Insights →

Recent Congressional trades

Biogen trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Maria Elvira Salazar	House	Sell	$15,001 - $50,000	Jul 7, 2026
Maria Elvira Salazar	House	Buy	$1,001 - $15,000	Jun 8, 2026
Maria Elvira Salazar	House	Buy	$50,001 - $100,000	Jun 8, 2026

BIIB FAQ

Is BIIB a buy?: Nama's AI scorecard currently rates Biogen Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is BIIB's P/E ratio?: Biogen trades at a trailing price-to-earnings ratio of 21.1.
When does BIIB report earnings?: Biogen's next scheduled report is on Feb 5, 2027. Analysts expect EPS of $2.84.
What is the BIIB price target?: The median analyst price target from 32 analysts is $270.00, with a range of $175.00 – $325.00.
Is BIIB Shariah compliant?: Nama's AAOIFI-style screen reads Biogen as Not Shariah Compliant. At least one of the three ratios or the industry test failed.